Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06113445 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 70 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Mar 19, 2026, no change to tracked fieldsv69-v70
  2. Primary completion date changed from estimate of Feb 25, 2026 to Feb 24, 2026v68
  3. Primary completion date: May 9, 2026 to Feb 25, 2026 Completion date: May 8, 2027 to Feb 24, 2027v67 Show 1 more changeShow less
    • Completion date: May 8, 2027 to Feb 24, 2027
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 444 to confirmed 467 · Study sites: 104 to 100v66 Show 2 more changesShow less
    • Enrollment target: estimated 444 to confirmed 467
    • Study sites: 104 to 100
  5. Study sites: 103 to 104v65
Show 44 earlier versionsHide 44 earlier versions
  1. Study sites: 104 to 103v64
  2. Study sites: 103 to 104v63
  3. Study sites: 104 to 103v62
  4. Study sites: 102 to 104v61
  5. Study sites: 106 to 102v60
  6. Study sites: 102 to 106v59
  7. Study sites: 106 to 102v58
  8. Study sites: 102 to 106v57
  9. Study sites: 106 to 102v56
  10. Study sites: 102 to 106v55
  11. Study sites: 106 to 102v54
  12. Study sites: 102 to 106v53
  13. Study sites: 106 to 102v52
  14. Study sites: 102 to 106v51
  15. Study sites: 106 to 102v50
  16. Study sites: 102 to 106v49
  17. Study sites: 106 to 102v48
  18. Study sites: 102 to 106v47
  19. Study sites: 106 to 102v46
  20. Study sites: 102 to 106v45
  21. Study sites: 106 to 102v44
  22. Study sites: 102 to 106v43
  23. Study sites: 106 to 102v42
  24. Study sites: 102 to 106v41
  25. Study sites: 104 to 102v40
  26. Study sites: 100 to 104v39
  27. Study sites: 103 to 100v38
  28. Study sites: 99 to 103v37
  29. Study sites: 103 to 99v36
  30. Study sites: 99 to 103v35
  31. Study sites: 103 to 99v34
  32. Study sites: 99 to 103v33
  33. Study sites revised (99)v32 See this version in full on ClinicalTrials.gov ↗
  34. Study sites: 103 to 99v31
  35. Study sites: 99 to 103v30
  36. Study sites: 103 to 99v29
  37. Study sites: 99 to 103v28
  38. Study sites: 103 to 99v27
  39. Study sites: 99 to 103v26
  40. Study sites: 98 to 99v25
  41. Study sites: 101 to 98v24
  42. Study sites: 96 to 101v23
  43. Study sites revised (96)v22 See this version in full on ClinicalTrials.gov ↗
  44. Study sites: 89 to 96v21
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Trial Details
NCT Number NCT06113445
Lead Sponsor Incyte Corporation
Conditions NonSegmental Vitiligo
Enrollment 467 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov